Department of Neurology, Yale University School of Medicine, 15 York St, LCI Suite 710, New Haven, CT, 06510, USA.
Clinical Neurosciences Imaging Center, Yale University School of Medicine, New Haven, CT, USA.
Brain Imaging Behav. 2021 Oct;15(5):2269-2282. doi: 10.1007/s11682-020-00420-5. Epub 2020 Nov 26.
Wilson disease (WD) can manifest with hepatic or neuropsychiatric symptoms. Our understanding of the in vivo brain changes in WD, particularly in the hepatic phenotype, is limited. Thirty subjects with WD and 30 age- and gender-matched controls participated. WD group underwent neuropsychiatric assessment. Unified WD Rating Scale neurological exam scores were used to determine neurological (WDN, score > 0) and hepatic-only (WDH, score 0) subgroups. All subjects underwent 3 Tesla anatomical and resting-state functional MRI. Diffusion tensor imaging (DTI) and susceptibility-weighted imaging (SWI) were performed only in the WD group. Volumetric, DTI, and functional connectivity analyses were performed to determine between-group differences. WDN and WDH groups were matched in demographic and psychiatric profiles. The entire WD group compared to controls showed significant thinning in the bilateral superior frontal cortex. The WDN group compared to control and WDH groups showed prominent structural brain changes including significant striatal and thalamic atrophy, more subcortical hypointense lesions on SWI, and diminished white matter integrity in the bilateral anterior corona radiata and corpus callosum. However, the WDH group also showed significant white matter volume loss compared to controls. The functional connectivity between the frontostriatal nodes was significantly reduced in the WDN group, whereas that of the hippocampus was significantly increased in the WDH group compared to controls. In summary, structural and functional brain changes were present even in neurologically non-manifesting WD patients in this cross-sectional study. Longitudinal brain MRI scans may be useful as biomarkers for prognostication and optimization of treatment strategies in WD.
威尔逊病 (WD) 可表现为肝性或神经精神症状。我们对 WD 患者体内大脑变化的了解有限,特别是在肝表型方面。本研究纳入 30 名 WD 患者和 30 名年龄和性别匹配的对照组。WD 组进行神经精神评估。采用统一 WD 评分量表 (Unified WD Rating Scale) 的神经检查评分,确定神经型 (WDN,评分>0) 和肝型 (WDH,评分 0) 亚组。所有受试者均进行 3T 解剖和静息态功能磁共振成像。仅在 WD 组进行弥散张量成像 (DTI) 和磁敏感加权成像 (SWI)。进行容积成像、DTI 和功能连接分析,以确定组间差异。WDN 和 WDH 组在人口统计学和精神科特征方面相匹配。与对照组相比,整个 WD 组双侧额上回皮质变薄。与对照组和 WDH 组相比,WDN 组表现出明显的结构性脑改变,包括纹状体和丘脑萎缩,SWI 上更多的皮质下低信号病变,以及双侧额前放射冠和胼胝体的白质完整性下降。然而,与对照组相比,WDH 组也表现出明显的白质体积丢失。与对照组相比,WDN 组的额-纹状体节点之间的功能连接显著减少,而 WDH 组的海马功能连接显著增加。总之,在这项横断面研究中,即使是神经表现正常的 WD 患者也存在结构性和功能性脑改变。纵向脑 MRI 扫描可能有助于作为预测标志物,并优化 WD 的治疗策略。